Quebec

Researchers are evaluating the outcomes of different coronary artery bypass grafting techniques in women with heart disease. The trial compares multiple arterial grafting MAG to single arterial grafting SAG to see if using multiple arterial grafts improves major heart and brain-related events and quality of life. This international randomized clinical trial includes 2,300 women to assess differences in survival, stroke, heart attacks, repeat surgeries, and hospital readmissions, as well as physical and mental health. Participants will be randomly assigned to one of two groups. One group receives a single arterial graft using the left internal thoracic artery plus additional venous grafts. The other group receives multiple arterial grafts, including the left internal thoracic artery and at least one other arterial graft such as the right internal thoracic artery or radial artery, with possible additional arterial grafts. The study uses the infrastructure of an existing trial and follows patients for at least 2.5 years after surgery. During the study, researchers collect data on major adverse cardiac and cerebrovascular events, along with quality of life measured by general and disease-specific questionnaires. Physical and mental health symptoms are also assessed. Follow-up includes tracking deaths, strokes, heart attacks, repeat procedures, and hospital stays. The trial aims to provide detailed information on outcomes and quality of life in women undergoing coronary bypass surgery over a long-term period.

This research aims to improve care for people with severe asthma by collecting detailed health and treatment information over five years. The study focuses on participants with severe asthma classified at GINA Step 4 uncontrolled or at GINA Step 5, aiming to understand treatment responses and disease progression. The Canadian cohort gathers data from seven sites to help develop better asthma treatments and care strategies. Participants will have their medical information collected through interviews and medical chart reviews at baseline and yearly follow-ups for five years. Data collected include demographics, medical history, asthma medications, test results such as blood work, lung function, allergen tests, and imaging. All data are anonymized and securely stored to protect participant privacy. During the study, researchers will track various measures such as blood eosinophil and IgE levels, exhaled nitric oxide, asthma control over the past month, medication use, asthma exacerbations, emergency visits, hospital admissions, and lung function tests. Participant confidentiality is maintained, and research records may be reviewed for monitoring. The study spans five years with annual visits to monitor health and treatment outcomes.

Researchers are studying critically ill adult patients who have been on invasive mechanical ventilation for more than 48 hours and are ready to undergo a Spontaneous Breathing Trial SBT to assess readiness for extubation. The study aims to improve and standardize decision-making for extubation in intensive care units by evaluating the Extubation Advisor EA, a bedside decision support tool that combines clinician assessments with predictive analytics to better predict extubation success and failure. This pilot trial will assess the feasibility of using the EA tool and inform a future larger randomized controlled trial to enhance extubation care and outcomes. In this randomized, single-blind trial, patients in the intervention group undergo an EA assessment during their SBTs. The device records waveform data and patient information, then generates a report that helps respiratory therapists and physicians decide whether to proceed with extubation. Patients in the control group receive standard care, with SBTs directed by clinicians without EA assessments or reports. The trial will assess recruitment feasibility, adherence to the protocol, and resource use over about 12 months. Participants will be monitored with assessments including the generation and delivery of EA reports and collection of clinical outcomes until hospital discharge. Researchers will evaluate the trials success based on recruitment rates, consent and randomization rates, adherence to intervention protocols, crossover occurrences, and completeness of clinical data. They will also assess the usefulness of the EA reports and measure institutional costs and time needed to implement the device. The study duration per participant varies according to clinical care and hospital stay.

This research aims to evaluate the effect of adding two questions and pictures to the validated Psoriasis Epidemiology Screening Tool PEST for diagnosing psoriatic arthritis PsA in adults with moderate-to-severe plaque psoriasis PsO in Canada. The study focuses on patients who are candidates for biologic Disease-Modifying Antirheumatic Drugs bDMARDs. It seeks to improve screening methods for PsA in this population. Participants will complete a modified PEST questionnaire called PESTpictures2 at their first dermatologist visit. This tool includes the original PEST questions, two extra questions about morning stiffness and night pain, and pictures illustrating joint symptoms. Those who screen positive will have a follow-up visit with a rheumatologist to confirm a PsA diagnosis. An end-of-study remote visit with the dermatologist will document participants bDMARD treatment choices and status within up to 120 days. During the study, participants will fill out screening questionnaires and attend up to two clinical visitsone with a dermatologist and one with a rheumatologist if neededfollowed by a remote end-of-study visit. Researchers will measure how well the modified PEST predicts PsA diagnosis, patient experience with the questionnaire, and treatment decisions. The study will also collect surveys and interviews from dermatologists to assess the screening tools impact and acceptability.

This trial investigates the efficacy and safety of benralizumab as an additional treatment for people aged 12 to 75 with uncontrolled eosinophilic asthma. These participants are already treated with a medium-dose inhaled corticosteroid and long-acting beta2-agonist ICS-LABA. The study compares adding benralizumab to increasing the inhaled therapy to a higher dose ICS-LABA. The research is a randomized, double-blind, active-controlled phase 3b trial designed to evaluate these treatments in people with a history of eosinophilic asthma who remain uncontrolled on medium-dose ICS-LABA with or without other controllers except oral corticosteroids. Participants are randomly assigned to one of two groups one receives benralizumab 30 mg by subcutaneous injection along with medium-dose ICS-LABA, and the other receives a placebo injection plus high-dose ICS-LABA. Doses of benralizumab or placebo are given every 4 weeks for the first three doses, then every 8 weeks, with up to seven injections during the study. The study treatment schedules continue for 48 weeks. During the study, participants will undergo assessments including lung function tests, asthma control questionnaires, and quality of life surveys. Researchers will track the annual rate of asthma exacerbations, time to first exacerbation, and safety events throughout the 48-week period. Compliance with asthma controller medication is monitored via daily diaries. This comprehensive evaluation helps understand the impact of adding benralizumab compared to increasing inhaled therapy dose in uncontrolled eosinophilic asthma.

Researchers are evaluating the safety and effectiveness of volrustomig in women with high-risk locally advanced cervical cancer FIGO 2018 stage IIIA to IVA who have not experienced disease progression following platinum-based concurrent chemoradiation therapy CCRT. This phase III, randomized, double-blind, placebo-controlled global study aims to compare volrustomig with a placebo to gain insights into treatment outcomes for this patient group. Participants will be randomly assigned in a 11 ratio to receive either volrustomig or a placebo by intravenous infusion. The study compares these two groups over time to assess progression-free survival and other important outcomes. Treatment is given after patients complete platinum-based CCRT and have no disease progression. The study includes long-term follow-up for up to approximately seven years to monitor various measures such as survival, response rates, and side effects. Throughout the study, participants will undergo regular assessments including tumor sample analysis, physical exams, and evaluations of organ function and overall health. Researchers will track progression-free survival, overall survival, response rates, and patient-reported symptoms and quality of life. Safety and adverse events related to volrustomig will also be monitored closely during the study and follow-up period. Participation involves a long-term commitment with ongoing monitoring for up to seven years.